Selective coactivation of α7- and α4β2-nicotinic acetylcholine receptors reverses beta-amyloid–induced synaptic dysfunction

Jessica P. Roberts1,2,4, Sarah A. Stokoe1,2,4, Matheus F. Sathler2, Robert A. Nichols1, and Seonil Kim1,2,*

From the 1Molecular, Cellular and Integrative Neurosciences Program and 2Department of Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA; and 3Department of Cell and Molecular Biology, University of Hawaii at Manoa, Honolulu, Hawaii, USA

Received for publication, November 4, 2020, and in revised form, February 2, 2021 Published, Papers in Press, February 9, 2021

Edited by Paul Fraser

Beta-amyloid (Aβ) has been recognized as an early trigger in the pathogenesis of Alzheimer’s disease (AD) leading to synaptic and cognitive impairments. Aβ can alter neuronal signaling through interactions with nicotinic acetylcholine receptors (nAChRs), contributing to synaptic dysfunction in AD. The three major nAChR subtypes in the hippocampus are composed of α7-, α4β2-, and α3β4-nAChRs. Aβ selectively affects α7- and α4β2-nAChRs, but not α3β4-nAChRs in hippocampal neurons, resulting in neuronal hyperexcitation. However, how nAChR subtype selectivity for Aβ affects synaptic function in AD is not completely understood. Here, we showed that Aβ associated with α7- and α4β2-nAChRs but not α3β4-nAChRs. Computational modeling suggested that two amino acids in α7-nAChRs, arginine 208 and glutamate 211, were important for the interaction between Aβ and α7-containing nAChRs. These residues are conserved only in the α7 and α4 subunits. We therefore mutated these amino acids in α7-containing nAChRs to mimic the α3 subunit and found that mutant α7-containing receptors were unable to interact with Aβ. In addition, mutant α3-containing nAChRs mimicking the α7 subunit interact with Aβ. This provides direct molecular evidence for how Aβ selectively interacted with α7- and α4β2-nAChRs, but not α3β4-nAChRs. Selective coactivation of α7- and α4β2-nAChRs also sufficiently reversed Aβ-induced AMPA receptor dysfunction, including Aβ-induced reduction of AMPA receptor phosphorylation and surface expression in hippocampal neurons. Moreover, costimulation of α7- and α4β2-nAChRs reversed the Aβ-induced disruption of long-term potentiation. These findings support a novel mechanism for Aβ’s impact on synaptic function in AD, namely, the differential regulation of nAChR subtypes.

Alzheimer’s disease (AD) is the predominant cause of dementia in the elderly, which is characterized by two histopathological hallmarks, beta-amyloid peptide (Aβ)-containing senile plaques and hyperphosphorylated tau-based neurofibrillary tangles (1). One of the early cognitive symptoms of AD is hippocampus-dependent memory impairments (2). Although neurodegeneration in AD is associated with multiple cellular abnormalities including tauopathies, mitochondrial dysfunction and oxidative stress, neuroinflammation, and gliosis (3, 4), many studies have provided evidence that oligomeric Aβ triggers synaptic dysfunction and loss of hippocampus-dependent memory in AD (4–6). In particular, accumulation of Aβ in the prodromic stage of AD is strongly associated with Aβ’s contribution to the synaptic dysfunction (6, 7). Although deficits in many neurotransmitter systems, including γ-aminobutyric acid (GABA) and serotonin, are associated with the progression of AD, the early symptoms appear to correlate strongly with dysfunction of cholinergic and glutamatergic synapses (6). However, the precise mechanisms of Aβ-induced deficits in these synapses remain to be determined.

The cholinergic system has been postulated to be a primary target in AD (8). A loss of cholinergic function is strongly associated with the onset of memory deficits in AD (9). Specifically, the loss of basal forebrain cholinergic neurons and altered nicotinic acetylcholine receptor (nAChR) expression in multiple regions of the brain, including in the hippocampus, are prominent pathological hallmarks in AD (10–12). In contrast, the expression of most muscarinic acetylcholine receptor subtypes is relatively unaltered in AD (13, 14). The nAChR-mediated cholinergic modulation of hippocampal synaptic plasticity, such as long-term potentiation (LTP) and long-term depression, plays a critical role in learning and memory (15). Of importance, cholinergic synapses in the hippocampus are impaired by Aβ in the early stage of AD (16). Indeed, Aβ can alter neuronal signaling through interactions with nAChRs, ultimately contributing to synaptic dysfunction in AD (reviewed in (17)). There are diverse lines of evidence that molecular interactions between Aβ and nAChRs affect receptor function in the early stages of AD (18–20). Nonetheless, contradictory results have been reported describing the effects of Aβ on nAChR physiology. For example, Aβ has been reported to bind to these receptors and produce functional receptor activation or inhibitory effects, depending on Aβ concentration, type of preparation (i.e., monomers, soluble oligomers, or fibrils), and incubation times (21–23). Therefore,

*For correspondence: Seonil Kim, seonil.kim@colostate.edu.

These authors contributed equally to this work.
there is a need to determine how Aβ specifically affects nAChRs and contributes to AD pathogenesis.

Although nearly 30 subtypes of neuronal nAChRs have been reported, the three major nAChR subtypes in the hippocampus are composed of α7, α4β2, and α3β4 subunits (24–26). Most of the current US Food and Drug Administration-approved drugs for AD (acetylcholinesterase inhibitors) inhibit the general breakdown of acetylcholine, which potentially stimulates all types of nAChRs. Thus, it is not surprising that these receptor modulators are only moderately effective (12, 27, 28). In addition, the observation that Aβ accumulates in brain regions enriched for α4β2- and α7-nAChRs may provide an important clue for the selective vulnerability of the hippocampus to Aβ toxicity given the high-affinity interaction between Aβ and these nAChRs (29–32).

Our previous work using Ca2+ imaging in cultured hippocampal neurons has shown that Aβ selectively inhibits α7- and α4β2-nAChRs together, but not α3β4-nAChRs (32), indicating that distinct nAChR subtypes are differentially affected in AD. As nAChRs are more prominently expressed in inhibitory interneurons than excitatory cells in the hippocampus (33, 34), nAChR-mediated cholinergic activity in the hippocampus may be biased toward altering the excitability of inhibitory interneurons. In line with this idea, our previous work demonstrates that Aβ induces neuronal hyperexcitation, an important characteristic in AD linked to network hyperexcitability and consequential dysfunction in brain rhythms (5), in cultured hippocampal excitatory neurons by predominantly reducing neuronal activity in inhibitory neurons via selective inhibition of α7- and α4β2-nAChRs, but not α3β4-nAChRs (32). Consistent with these findings, considerable evidence suggests that Aβ exerts subtype-specific inhibition of α7- and/or α4β2-nAChR function without affecting α3β4-nAChRs (21–23, 32, 35–39). The expression of α7 and α4 subtypes is also more significantly reduced in the cortex and hippocampus of patients with AD compared with α3-type receptors (40, 41). This suggests that Aβ-induced disruption of selective nAChR function may induce synaptic and neuronal dysfunction in the hippocampus, leading to cognitive decline in AD. Therefore, strategies that selectively regulate nAChRs in the hippocampus can reverse the pathological Aβ effects on AD pathology, which may improve cognitive function. However, how nAChR subtype selectivity of Aβ affects synaptic function in AD is not completely understood.

Previous work using structure–function analysis has shown that the hydrophilic N-terminal domain of Aβ affects α7- and α4β2-nAChR function, elevating presynaptic Ca2+ levels in a model reconstituted rodent neuroblastoma cell line and isolated mouse nerve terminals (42). Furthermore, the activity of the Aβ N terminus largely comes from a sequence surrounding a putative histidine-based metal binding site, YEVHHQ (42). More importantly, this hexapeptide Aβ core sequence (Aβcore) is found to dock into the ligand-binding site of nAChRs and reverse Aβ-induced neuronal apoptotic death, synaptic plasticity, and fear memory deficits (43). In addition, mutations of tyrosine to serine and the two histidine residues to alanines in Aβcore (SEVAAQ) substantially reduce its neuroprotective effects, identifying these residues as critical to the neuroprotective actions of the Aβcore (43). These findings are consistent with earlier evidence showing that a different core Aβ fragment, Aβ12–28, that contains the critical residues of the Aβcore is sufficient to prevent Aβ from binding to α7-nAChRs and reverse Aβ-induced inhibition of α7-nAChRs (44). Finally, a recent study shows that the formation of the Aβ–α4β2-nAChRs complex is based on the interaction of a part of Aβcore sequence (EVHH) with α4β2-containing receptors, and blocking this interaction prevents Aβ42-induced inhibition of α4β2-nAChRs (45). This thus suggests that interrupting the association of Aβ with nAChRs may be neuroprotective against Aβ-induced neuronal dysfunction in AD, although the differential impact of the Aβcore on the three major nAChRs in the hippocampus remains to be explored.

Here, we investigated the Aβ interaction with nAChRs in Aβ-induced Ca2+ hyperexcitation in cultured hippocampal neurons, assessing the impact of the neuroprotective, nontoxic N-terminal Aβcore to reverse the hyperexcitation. In addition, we assessed the selective interaction of Aβ with specific nAChRs and identified the amino acids, arginine and glutamate, within the loop C of the α7 and α4 subunits to be critical for these interactions. Moreover, we examined the impact of selective coactivation of α7- and α4β2-nAChRs on Aβ-induced synaptic dysfunction, including regulation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors (AMPARs). The findings have implications for regulation of nAChRs as therapeutic targets in the hippocampus for neuroprotection in AD.

**Results**

**Interaction between Aβ and nAChRs in Aβ-induced Ca2+ hyperexcitation and reversal by the neuroprotective Aβcore**

Altering the interaction of Aβ with α7- and α4β2-nAChRs may be neuroprotective against Aβ-induced neuronal dysfunction in AD. We thus examined whether the interaction of Aβ1–42 (Aβ42) with nAChRs is important for neuronal hyperactivity by using the Aβcore peptide (42, 43). As neuronal Ca2+ indicates neuronal activity (46), we measured Ca2+ activity in cultured 12 to 14 days in vitro (DIV) mouse hippocampal pyramidal neurons transfected with GCaMP6f (a genetically encoded Ca2+ indicator) as described previously (32, 47). We treated neurons with soluble Aβ42 oligomers (sAβ42) and determined Ca2+ activity in hippocampal neurons immediately after treatment. We found active spontaneous Ca2+ transients in the control condition (250 nM scrambled Aβ42; sAβ42) (Fig. 1). Consistent with the previous findings (32), the total Ca2+ activity in 250 nM sAβ42-treated cells was significantly higher than in sAβ42-treated controls (sAβ42, 1.48 ± 0.95 ΔF/Fmin; p = 0.0009), confirming that soluble 250 nM Aβ42 oligomers were sufficient to increase neuronal Ca2+ activity (Fig. 1).

Of note, when 1 μM of Aβcore (YEVHHQ) was added in conjunction with 250 nM sAβ42, Aβcore treatment was able to reverse sAβ42-induced Ca2+ hyperexcitation (sAβ42+Aβcore, 0.98 ± 0.93 ΔF/Fmin; p = 0.04) (Fig. 1). However, the Aβcore had no effect on GCaMP6f activity in sAβ42-treated
control neurons (sAβ42+αβcore, 0.85 ± 0.48 ΔF/ΔF_min) (Fig. 1), which is consistent with the previous finding that Aβcore treatment had no prolonged effect on Ca^{2+} levels in differentiated mouse neuroblastoma cells (43). Next, we added 1 μM inactive Aβcore (SEVAAQ) in oAβ42-treated neurons and found that it was unable to reverse oAβ42 effects on Ca^{2+} activity (oAβ42+inactive Aβcore, 1.77 ± 1.03 ΔF/ΔF_min) (Fig. 1). Finally, inactive Aβcore treatment had no effect on neuronal activity in sAβ42-treated control neurons (sAβ42+inactive Aβcore, 0.95 ± 0.60 ΔF/ΔF_min) (Fig. 1). We thus demonstrated that cotreatment with the Aβcore peptide following application of oAβ42 significantly attenuated oAβ42-induced Ca^{2+} hyperactivity, possibly owing to the inhibition of the interaction between Aβ42 and nAChRs.

Aβ selectively interacts with α7- and α4β2-nAChRs but not α3β4-nAChRs

Many studies support that Aβ can physically interact with α7-, α4- and β2-containing nAChRs in various model systems (17, 31, 48, 49), whereas Aβ is unable to affect α3- and β4-containing receptor function when heterologously expressed in Xenopus oocytes (23). Nonetheless, the exact nature of the selective Aβ interaction with nAChRs is not fully defined. To directly measure interactions of Aβ with nAChR subunits, we carried out a series of coimmunoprecipitation (co-IP) analyses in transfected human embryo kidney (HEK293) cells, as described (50). Lysates from cells overexpressing human α7-nAChR-GFP receptors were incubated with 2 μM Aβ42 and 5 μM active Aβcore peptide for 18 h and immunoprecipitated with an anti-GFP antibody. We found that the antibody pulled down α7-nAChR-GFP receptors but not Aβ42 (Fig. S2A). We next used the inactive Aβcore peptide and found that it had no effect on the association between Aβ42 and α7-nAChRs (Fig. S2B). This suggests that the Aβcore peptide can inhibit the interaction between Aβ42 and α7-nAChRs, which may underlie, at least in part, the neuroprotective effects of the Aβcore peptide, in addition to its direct action on Aβ-regulated receptors (43).

Computer-simulated docking studies using the homology model of the human α7-nAChRs derived from the X-ray structure of the acetylcholine-binding protein (AChBP) and human Aβ show that the N terminus of Aβ is predicted to bind to the loop C of the α7 subunit, which is located within the binding interface of two α7 subunits (43, 51, 53–55). We used the CABS-dock server for flexible protein–peptide docking (56) to analyze interactions of the α7 nAChR-AChBP chimera

**Figure 1. Interaction between Aβ42 and nAChRs is important for Aβ42-induced Ca^{2+} hyperexcitation.** Representative traces of GCaMP6f fluorescence intensity in hippocampal neurons in each condition and a summary graph of the normalized average of total Ca^{2+} activity in neurons treated with either 250 nM sAβ42 (black) or 250 nM oAβ42 (red) in the absence or presence of 1 μM Aβcore or inactive 1 μM Aβcore (inAβcore) (n = number of neurons [sAβ42, n = 127; sAβ42+αβcore, n = 23; sAβ42+inAβcore, n = 32; oAβ42, n = 71; oAβ42+αβcore, n = 30; and oAβ42+inAβcore, n = 31], **p < 0.01 and ****p < 0.0001 and, one-way ANOVA, Fisher’s least significant difference test).
Coactivation of α7- and α4β2-nAChRs reverses Aβ effects

Figure 2. Aβ42 selectively interacts with α7- and α4β2-nAChRs, but not α3β4-nAChRs. A, Co-IP shows Aβ42 interacts with α7-nAChRs. B, Co-IP shows Aβ42 binds to α4β2-nAChRs. C, Co-IP shows Aβ42 is unable to interact with α3β4-nAChRs. D, sequence and numbering of human α7-nAChRs in the loop C region and its alignment with related human and mouse nAChR sequences. Y210 (E211 in mouse) is conserved in both human and mouse nAChRs. E211 is the ligand-binding residue and conserved in all human and mouse α subunits. R208 (blue) and E211 (green) are predicted to be critical for interaction with the N terminus of Aβ, which are conserved only in both human and mouse α4 and α7 subunits except mouse α7 receptors that have positive-charged lysine (light blue), which is similar to positive-charged arginine. However, both mouse and human α3 receptors have uncharged residues in both positions (red). E, Co-IP shows Aβ42 is unable to interact with the α7 R208I mutant. F, Co-IP shows Aβ42 is unable to bind to the α7 E211N mutant. G, Co-IP shows Aβ42 is unable to interact with the α3 I284R mutant. H, Co-IP shows Aβ42 cannot interact with the α3 N287E mutant. I, double α3 I284R/N287E mutant is able to pull down Aβ42. Co-IP, coimmunoprecipitation.

(Protein Data Bank code: 1UW6) (55) and human N terminus of Aβ (Fig. S3). Three amino acids in the loop C of α7 nAChRs, arginine (R208), tyrosine (Y210), and glutamate (E211), were predicted to be critical for interactions of the α7 subunit with Aβ (Fig. 2D). Among them, Y210 is the ligand-binding residue and conserved in all human and mouse α3, α4, and α7 subunits (55) (Fig. 2D). Mutation studies have shown that Y210 is essential for acetylcholine binding and Aβ interactions (51, 55). Of interest, both R208 and E211, noncontact residues, are only conserved in human α4 and α7 subunits but not in the α3 subunit (Fig. 2D). Of importance, R208 in the human α7 subunit contains a positively charged side chain, and mouse α7 subunits contain lysine (K), a positively charged amino acid, instead of arginine (Fig. 2D). However, both mouse and human α3 subunits contain hydrophobic isoleucine (I) instead of positively charged arginine in the human α7 subunit or lysine in the mouse α7 subunit (Fig. 2D). Moreover, E211 in the human α7 subunit contains a negatively charged side chain, which is conserved in both human and mouse α4 and α7 subunits, while both mouse and human α3 subunits include uncharged asparagine (N) (Fig. 2D). Mutations in R208 and E211 in α7-nAChRs alter the binding affinity of the receptor to acetylcholine (55). Thus, it is possible that these two charged residues are responsible for the nAChR subtype selectivity of Aβ interactions. To test this idea, we generated mutant α7 subunits by substituting R208 for isoleucine (R208I) or E211 for asparagine (E211N) to mimic the α3 subunit (Fig. 2F). Co-IP experiments were performed with lysates from HEK293 cells overexpressing human α7-nAChR-R208I-GFP or α7-nAChR-E211N-GFP receptors. We found that Aβ42 was unable to interact with either mutant α7-nAChR, a loss-of-function effect (Fig. 2, E and F). Furthermore, we made mutant α3 subunits by substituting I284 for arginine (I284R) or N287 for glutamate (N287E) to mimic the α7 subunit to test whether these mutants would show gain-of-function effects on the interaction between Aβ42 and the receptors. We carried out co-IP experiments with lysates from HEK293 cells overexpressing human α3-nAChR-I284R-GFP or α3-nAChR-N287E-GFP receptors with human β4 subunits. Both mutant receptors were unable to pull down Aβ42 (Fig. 2, G and H). We next generated a double mutant receptor that contained both I284R and N287E (Fig. 2F). In contrast to the single mutations, we found that the double α3 mutant was able to interact with Aβ42 when α3-nAChR-I284R/N287E-GFP and the β4 subunits were expressed in HEK293 cells (Fig. 2F). These data suggest that the charged arginine and glutamate residues in the loop C in the α4 and α7 subunits play important roles in the interaction between Aβ and nAChRs, providing direct molecular evidence of how Aβ selectively interacts with α7- and α4β2-nAChRs, but not α3β4-nAChRs.

Selective coactivation of α7- and α4β2-nAChRs reverses Aβ-induced reduction of AMPAR surface expression

Aβ has been reported to affect the function of AMPARs, which are important in synaptic plasticity (57). Several studies
suggest that Aβ-induced Ca\(^{2+}\) hyperexcitation promotes AMPAR endocytosis, which ultimately decreases the surface expression of AMPA receptor subunits GluA1 and GluA2, a cellular mechanism underling Aβ-induced depression of AMPAR-mediated synaptic transmission (32, 58–61). Given that selective coactivation of α7- and αβ2-nAChRs reverses Ca\(^{2+}\) hyperexcitation in cultured neurons (32), we examined whether selective coactivation of α7- and αβ2-nAChRs reversed the Aβ effects on surface expression of AMPARs. We measured surface expression of AMPARs by biotinylation after 1 μM soluble Aβ42 oligomers (αβ42) were applied to cultured hippocampal neurons for 1 h. Scrambled Aβ42 (sAβ42) was treated in neurons as the control. Consistent with the previous findings (32), αβ42 treatment reduced surface expression of AMPAR subunits GluA1 and GluA2 (Fig. 3, A–C and Tables 1–3). Next, subtype-specific nAChR agonists, 1 μM PNU-282987 (α7), 2 μM RJR-2403 Oxalate (αβ2), or 1 μM NS-3861 (α3β4), were incubated with αβ42 or sAβ42 for 1 h to activate each nAChR subtype. Activation of α7- or αβ2- or α3β4-nAChRs singularly was unable to reverse the Aβ effects on GluA1 and GluA2 surface levels (Fig. 3A and Table 1). Stimulation of each receptor by themselves also had no effect on GluA1 and GluA2 surface expression in control neurons (Fig. 3A and Table 1). Of importance, when we concurrently activated α7- and αβ2-nAChRs for 1 h using 1 μM PNU-282987 and 2 μM RJR-2403 Oxalate, GluA1 and GluA2 surface levels were restored to normal levels in cells treated with αβ42 (Fig. 3B and Table 2). However, stimulation of α7- and αβ4-nAChRs or αβ2- and αβ4-nAChRs was unable to reverse the Aβ effects (Fig. 3B and Table 2). In addition, costimulation of two nAChR subtypes had no effect on GluA1 and GluA2 surface levels in sAβ42-treated neurons (Fig. 3B and Table 2). Next, we activated all three types of nAChRs together by treating neurons with the three agonists for 1 h and found no neuroprotective effect on Aβ-induced reduction of AMPAR surface levels (Fig. 3C and Table 3). Stimulation of α7-, αβ4- and αβ2-nAChRs together was unable to alter surface GluA1 and GluA2 levels in sAβ42-treated control cells (Fig. 3C and Table 3). Of interest, 1 μM carbachol, a cholinergic agonist, was also unable to reverse the Aβ effects on AMPAR surface expression (Fig. 3C and Table 3). Furthermore, carbachol was sufficient to reduce surface GluA1 but not GluA2 expression in control cells, suggesting that global stimulation of acetylcholine receptors may exacerbate the Aβ effects in neurons (Fig. 3C and Table 3). This suggests that selective coactivation of α7- and αβ2-nAChRs is required to abolish the Aβ effects on AMPAR surface expression.

**Coactivation of α7- and αβ2-nAChRs reverses Aβ-induced impaired AMPAR phosphorylation and synaptic plasticity**

Several studies suggest that Aβ-induced Ca\(^{2+}\) hyperexcitation elevates the activity of Ca\(^{2+}\)-dependent phosphatase, calcineurin, which, in turn, will promote AMPAR endocytosis via dephosphorylation of AMPAR subunit GluA1 at serine

---

**Figure 3. Selective coactivation of α7- and αβ2-nAChRs reverses Aβ-induced reduction of AMPAR surface expression.** Representative immunoblots of input (I) and surface (S) levels and quantitative analysis in (A) single activation of each nAChR (n = 6 immunoblots from three independent cultures duplicated, *p < 0.05, **p < 0.01, and ***p < 0.001, one-way ANOVA, Fisher’s least significant difference [LSD] test). B, double activation of each nAChR (n = 6 immunoblots from three independent cultures duplicated, *p < 0.05, **p < 0.01, and ***p < 0.001, one-way ANOVA, Fisher’s LSD test). C, triple activation and cholinergic stimulation (n = 6 immunoblots from three independent cultures duplicated, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, one-way ANOVA, Fisher’s LSD test).
845, a residue that plays a crucial role in AMPAR surface expression during synaptic plasticity (32, 58, 59, 62). In fact, previous studies reveal that Aβ reduces AMPAR GluA1 phosphorylation at serine 845 (pGluA1), which is strongly associated with disrupted LTP in AD (32, 58, 61). Consistently, hippocampal LTP can be blocked by either direct exogenous Aβ or Aβ2-nAChRs when we treated neurons with 1 μM Aβ42 or sAβ42 for 1 h and measured basal pGluA1 levels (Fig. 4A). As shown before (32), Aβ42 treatment decreased pGluA1 compared with the sAβ42-treated control (sAβ42, 1.00 and Aβ42, 0.48 ± 0.25, p = 0.0424) (Fig. 4, A and B). Of significance, Aβ- induced reduction of pGluA1 was reversed by costimulation of α7- and α4β2-nAChRs when we treated neurons with 1 μM PNU-282987 and 2 μM JR-2403 Oxalate for 1 h (αAβ2-agonists, 1.27 ± 0.91, p = 0.003) (Fig. 4, A and B). However, coactivation of these receptors in control cells had no effect on
pGluA1 levels (sAβ42+agonists, 0.92 ± 0.36) (Fig. 4, A and B). We next treated neurons with a glycine-based medium, well established to induce a form of chemical LTP (cLTP), as shown previously (62, 67). We treated neurons with 1 μM αAβ42 or sAβ42 for 1 h, induced cLTP, and measured pGluA1 levels (Fig. 4A). As shown previously (62, 67), following cLTP induction, pGluA1 levels were significantly elevated in control neurons, an indication of LTP expression (Fig. 4A). However, pGluA1 levels were significantly lower in αAβ42-treated neurons compared with sAβ42-treated control cells after cLTP induction (sAβ42, 1.00 and αAβ42, 0.55 ± 0.33, p = 0.0075) (Fig. 4, A and C), an indication of impaired synaptic plasticity. Of importance, normal pGluA1 levels were restored when we activated both α7- and α4β2-nAChRs and induced cLTP in αAβ42-treated neurons (αAβ42+agonists, 0.91 ± 0.27, p = 0.0359) (Fig. 4, A and C). However, coactivation of these receptors in control cells had no effect on pGluA1 levels following cLTP induction (sAβ42+agonists, 1.14 ± 0.61) (Fig. 4, A and C). Thus, coactivation of α7- and α4β2-nAChRs was sufficient to reverse the Aβ effects on AMPAR phosphorylation and cLTP.

**Discussion**

Current therapeutic approaches to AD suffer from lack of specificity and poor efficacy. Preclinical approaches based on altering Aβ have failed in clinical trials. Consequently, novel approaches are being explored, including targeting receptors regulated by Aβ. Nicotinic receptors have emerged as potential targets for reversing cognitive deficits in AD (68), owing to their noted potent regulation by Aβ, but there remains a need to determine the roles of specific nAChR subtypes in AD. In this study, we demonstrate that the interaction between Aβ and nAChRs plays an important role in Aβ-induced alteration of synaptic and neuronal activity. We provided further evidence for Aβ’s selective interaction with α7- and α4β2-nAChRs but not α3β4-receptors, and selective stimulation of α7- and α4-containing nAChRs was shown to be neuroprotective against the Aβ effects on synaptic function. Of note, we identified two key amino acids, arginine and glutamate, present in the loop C of the α7 and α4 subunits, but not the α3 subunit, that are important for interaction with Aβ, providing a molecular mechanism for Aβ’s selective inhibition of α7- and α4β2-nAChRs.

Based on the present findings, we propose the following model (Fig. 5). Given that nAChRs are more prominently expressed in inhibitory interneurons in the hippocampus, soluble Aβ42 oligomers selectively interact with α7- and α4β2-nAChRs but not α3β4-nAChRs and reduce neuronal activity in inhibitory cells, leading to a decrease in the release of GABA onto hippocampal excitatory neurons (Fig. 5A). This is supported by our previous work in which stimulation of GABAA receptors is sufficient to reverse Aβ42-induced Ca2+ hyperactivity in cultured neurons (32). Excitatory cells will thus have increased neuronal Ca2+ activity, consequently elevating the activity of calcineurin (32) (Fig. 5A) and other Ca2+ signaling pathways. This promotes the dephosphorylation of the AMPAR subunit, GluA1, which allows for AMPAR endocytosis, resulting in an overall decrease of AMPAR surface expression (Fig. 5A). This ultimately contributes to disruption of LTP (Fig. 5A) and may lead to cognitive decline. As Aβ42 inhibits both α7- and α4β2-nAChRs but not α3β4-nAChRs, costimulation of α7- and α4β2-nAChRs by using selective agonists can reverse the Aβ effects on synapses by restoring normal activity of both hippocampal inhibitory and excitatory cells (Fig. 5B). With restoration of normal Ca2+ activity, calcineurin activity decreases, leading to AMPAR phosphorylation and decreased AMPAR endocytosis, ultimately restoring normal LTP (Fig. 5B). Given that Aβ42 inhibits both α7- and α4β2-nAChRs, stimulation of each receptor by themselves has no neuroprotective effect (Fig. 3A).

Our co-IP experiments using mutant α7- and α3-containing receptors suggest that the charged arginine and glutamate residues in the loop C of α7- and α4β2 nAChRs are critical for the interaction of Aβ with these receptors. However, it is important to note that, as Aβ was added to the cell lysates and not the cell culture medium during co-IP, we are unable to rule out the possibility that Aβ may interact differently with surface nAChRs in situ on neurons. Nonetheless, a previous study identified that arginine 182 (R182) and glutamate 185 (E185), located in the loop C region of the α7-nAChR-AChBP chimera (equivalent to R208 and E211 in the native α7 subunits), do not have direct contact to agonists but impact the affinity of α7-nAChRs for ligands (55). In fact, the study revealed that R182 pairs with lysine 141 (K141), and E185 pairs with glutamate (E158) and aspartic acid 160 (D160), and these interactions provide electrostatic repulsion, which in native α7 may favor the open conformation of loop C, contributing to lower agonist affinity (55). It was further shown that mutations in any of these residues shift the concentration dependence of acetylcholine binding to the receptor to lower concentrations (higher affinity) by relief of electrostatic repulsion (55). Thus, we suggest that electrostatic repulsion generated by these residues may favor the open conformation of loop C, contributing to Aβ affinity. Therefore, a loss of one of these charged residues in the α7 subunit (R208I or E211N) disrupts the interaction of mutant α7-containing receptors with Aβ. Where α7-nAChRs are primarily present as homopentamers (31, 52), electrostatic repulsion would be established within the α7 subunits, and thus mutations of R208 or E211 disrupt this electrostatic repulsion, which may contribute to loss of binding to Aβ. In contrast to homomeric α7-nAChRs, α4- and α3-containing receptors exist as heteropentamers incorporating β subunits (69, 70). Of interest, glutamate in the loop C of the α4 subunit is likely to pair with a negatively charged residue in the β subunits, providing the electrostatic repulsion similar to α7 homopentamers (69). Thus, the β subunits may contribute to the binding affinity of the receptor to Aβ in α4β2- or α7β2-nAChRs expressed in hippocampal inhibitory neurons (71). Given that the α3 subunit contains noncharged amino acids in the loop C, a gain of charged residues in the loop C of α3-containing receptors may underlie an increased affinity of the receptors for Aβ42. In addition, other computational modeling studies show that E211 in the loop C of the α7 subunit is able to interact with Aβ42 and further suggest that
Coactivation of α7- and α4β2-nAChRs reverses Aβ effects

the similar interactions apply to α4β2-AChRs (72, 73). In sum, these findings suggest that the charged residues, arginine and glutamate, in the loop C of the α7- and α4β2-nAChRs are critical for Aβ interaction and its effect on the receptors. However, as dynamic conformational changes cannot be accurately predicted from static models, we are unable to exclude other conformations that might contribute to the interaction between Aβ and the receptors.

Of interest, costimulation of α4β2- and α7-nAChRs can prevent the Aβ effects in cultured neurons, whereas coadministration of agonists for three nAChR subtypes has no effect (Fig. 3C). Cholinergic signaling in GABAergic inhibitory networks is generally stronger than direct actions on glutamatergic neurons in the hippocampus, as nAChRs are more densely expressed on inhibitory interneurons than on excitatory cells (33, 74–78). It has been suggested that, in the hippocampus, α7-nAChRs are located on GABAergic inhibitory interneurons and a subset of glutamatergic neurons, whereas α4β2-nAChRs are mainly located on GABAergic cell bodies and nerve terminals. By contrast, α3β4-nAChRs appear to be primarily associated with glutamatergic neurons, although their precise localization remains to be determined (74, 76, 77, 79–88) (Fig. 5). Thus, costimulation of α7- and α4β2-nAChRs by selective agonists, PNU-282987 (PNU) and RJR-2403 Oxalate (RJR), can restore normal activity of both hippocampal inhibitory and excitatory cells, reversing Aβ-induced synaptic dysfunction. This restoration of normal Ca2+ activity prompts a decrease in calcineurin activity, leading to a decrease in hippocampal excitatory neurons. Consequently, excitatory cells have increased frequency of Ca2+ transients, resulting in elevated calcineurin (CaN) activity. Calcineurin then dephosphorylates the AMPA receptor (AMPAR) subunit, GluA1, promoting AMPAR endocytosis and resulting in an overall decrease of AMPAR surface expression. This ultimately contributes to disruptions of long-term potentiation.

B, reversal of Aβ-induced synaptic and neuronal dysfunction by costimulation with α7- and α4β2-nAChRs agonists. As Aβ42 inhibits both α7- and α4β2-nAChRs but not α3β4-nAChRs, costimulation of α7- and α4β2-nAChRs by selective agonists, PNU-282987 (PNU) and RJR-2403 Oxalate (RJR), can restore normal activity of both hippocampal inhibitory and excitatory cells, reversing Aβ-induced synaptic dysfunction. This restoration of normal Ca2+ activity prompts a decrease in calcineurin activity, leading to a decrease in AMPAR dephosphorylation and AMPAR endocytosis, ultimately restoring normal long-term potentiation. However, an agonist for α3β4-nAChRs, NS-3861 (NS), does not appear to have neuroprotective effects. Moreover, nonspecific stimulation of nAChRs by using three agonists together or carbachol is unable to reverse the Aβ effects on neuronal activity and synaptic function, emphasizing the importance of selective costimulation of nAChRs as potential therapeutic approaches.

Figure 5. Schematic model. A, impact of Aβ oligomers. In the hippocampus, α7- and α4β2-nAChRs are prominently expressed on inhibitory interneurons; thus, selective binding of soluble Aβ42 oligomers (oAβ42) to α7- and α4β2-nAChRs but not α3β4-nAChRs, reduces neuronal activity in inhibitory cells, leading to a decrease in the release of GABA onto hippocampal excitatory neurons. Consequently, excitatory cells have increased frequency of Ca2+ transients, resulting in elevated calcineurin (CaN) activity. Calcineurin then dephosphorylates the AMPA receptor (AMPAR) subunit, GluA1, promoting AMPAR endocytosis and resulting in an overall decrease of AMPAR surface expression. This ultimately contributes to disruptions of long-term potentiation.

B, reversal of Aβ-induced synaptic and neuronal dysfunction by costimulation with α7- and α4β2-nAChRs agonists. As Aβ42 inhibits both α7- and α4β2-nAChRs but not α3β4-nAChRs, costimulation of α7- and α4β2-nAChRs by selective agonists, PNU-282987 (PNU) and RJR-2403 Oxalate (RJR), can restore normal activity of both hippocampal inhibitory and excitatory cells, reversing Aβ-induced synaptic dysfunction. This restoration of normal Ca2+ activity prompts a decrease in calcineurin activity, leading to a decrease in AMPAR dephosphorylation and AMPAR endocytosis, ultimately restoring normal long-term potentiation. However, an agonist for α3β4-nAChRs, NS-3861 (NS), does not appear to have neuroprotective effects. Moreover, nonspecific stimulation of nAChRs by using three agonists together or carbachol is unable to reverse the Aβ effects on neuronal activity and synaptic function, emphasizing the importance of selective costimulation of nAChRs as potential therapeutic approaches.
treated with three agonists together would not change significantly, contributing to the unaltered AMPAR surface expression (Fig. 3C).

The current study focuses on the differential effects of Aβ on nAChR subtypes that lead to alterations in neuronal excitability and synaptic function. Consistent with previous findings using acetylcholinesterase inhibitors (74), we found that nonselective cholinergic activation exacerbates Aβ effects on hippocampal neurons (Fig. 3C), pointing to confounding effects of activating α3β4-α4β2 nAChRs, which may result in unexpected side effects, including imbalance of excitation and inhibition in hippocampal circuits. Therefore, acetylcholinesterase inhibitors are not very effective in slowing AD progression due to nonselective stimulation of acetylcholine receptors (90, 91). There are also discrepancies involving the use of nicotine treatment to stimulate nAChRs to alter cognitive function. For example, nicotinic agonists have been found to improve performance in a variety of memory tasks in rodents and nonhuman primate studies (68), whereas several other studies have failed to find significant enhancement of learning and memory by nicotine treatment (92). Part of the discrepancy may lay in the antagonistic effect of prolonged nicotine exposure, owing to induction of nAChR inactivation (desensitization). The extent to which nAChR subtype-selective agonists drive receptor inactivation, and their impact on intracellular signaling in Aβ neurotoxicity, remains to be determined (93). Nonetheless, nAChR agonists have consistently been suggested as promising approaches in the treatment of AD (94). However, clinical trials thus far have been challenged by adverse effects or minimal improvement (95). In particular, stimulating only one type of nAChR by using a subtype-specific agonist was found to either enhance cognitive performance or have no beneficial effect. For instance, selective α7-nAChR agonists have been reported to improve cognition in a variety of animal models (96–98), whereas another study has found they have almost no efficacy in learning and memory in mice (99). An α4β2-nAChR agonist alone can improve working memory only in young rats but not in older animals (100). It is thus not yet clear whether single activation of specific nAChR subtypes provides optimal efficacy in AD (94). We have also shown that activation of either α7- or α4β2-nAChRs singularly had no effect on Aβ-induced hyperexcitation (32) or α7- and α4β2-nAChR Aβ-induced reduction of AMPAR surface expression (Fig. 3A). By contrast, selective coactivation of α7- and α4β2-nAChRs was sufficient to reverse Aβ-induced neuronal hyperexcitation (32) and synaptic dysfunction (Figs. 3B and 4). Several subtype-specific agonists have been developed for clinical trials, but coactivation of nAChRs has not been applied for clinical trials yet (94); thus, the current study may lead to an innovative and novel therapeutic strategy for AD.

Experimental procedures

Mouse hippocampal neuron culture

Mouse hippocampal neuron cultures were prepared as described (32, 47, 101–103). Hippocampi were isolated from postnatal day 0 (P0) CD-1 (Charles River) mouse brain tissues and digested with 10 U/ml papain (Worthington Biochemical Corp). For Ca2+ imaging, mouse hippocampal neurons were plated on poly-D-lysine-coated glass-bottom dishes (5 × 10^5 cells) and imaged on DIV 12 to 14. For biotinylation assays and cLTP, hippocampal neurons were plated in 6-cm dishes (3 × 10^6 cells) and used on DIV 14. Cells were grown in Neurobasal medium (Life Technologies) with B27 supplement (Life Technologies), 0.5 mM Glutamax (Life Technologies), and 1% penicillin/streptomycin (Life Technologies). Colorado State University’s Institutional Animal Care and Use Committee reviewed and approved the animal care and protocol (978).

Reagents

Soluble Aβ42 oligomers or soluble scrambled Aβ42 oligomers were prepared as described (32, 104). One milligram of lyophilized human Aβ42 (Anaspec) or scrambled Aβ42 (Anaspec) was dissolved in 1 ml of 1,1,1,3,3,3-hexafluoro-2-propanol (Fisher Scientific) to prevent aggregation, portioned into 10-μg aliquots, air dried, and stored at −80 °C. For use in experiments, an aliquot was thawed at room temperature and then dissolved in 100% dimethyl sulfoxide, then diluted into PBS to make a 100 μM solution. The solution was incubated for 16 h at 4 °C and then diluted to a final concentration for use in experiments. The following agonists were used in this study: 1 μM PNU-120596 (Alomone Labs), 2 μM RJR-2403 Oxalate (Alomone labs), 1 μM NS-3861 (Tocris Bioscience), and 1 μM Carbamoylcholine chloride (carbachol) (Tocris Bioscience). Aβcore (YEYHHHQ) and inactive Aβcore (SEVAAQ) peptides were prepared as described (43).

HEK293 cell culture and transfection

HEK293 cells were grown in Dulbecco’s modified Eagle’s medium with fetal bovine serum (Life Technologies) and 1% penicillin/streptomycin (Life Technologies) and transfected by jetPRIME DNA and siRNA transfection reagent (Polyplus) according to the manufacturer’s protocol. Cells used for each experiment were from more than three independently prepared cultures. Two micrograms of human α7-nAChR-GFP plasmid was transfected into HEK293 cells to express the homopentameric form of α7-nAChRs. Both α3β4- and α4β2-nAChRs expressed by 1:1 α8 transfection ratio formed functional channels in HEK293 cells (105–108). Therefore, the α3 to β4 or α4 to β2 cDNA ratio in the mixture was kept equal (1:1, 1 μg each) for transfection to express α3β4- or α4β2-nAChRs in HEK293 cells.

DNA plasmids and mutagenesis

Human pcDNA3.1-CHRAN7-mGFP was a gift from Henry Lester (Addgene plasmid # 62629; http://n2t.net/addgene:62629; RRID:Addgene_62629) (109). Mouse nAChR alpha4 CFP was a gift from Henry Lester (Addgene plasmid # 15244; http://n2t.net/addgene_15244; RRID:Addgene_15244) (110). pCI-neoBeta2mccherry was a gift from Henry Lester (Addgene plasmid # 45097; http://n2t.net/addgene:45097; RRID:Addgene_45097). β4-nAChR (DPM negative control) was a gift
from Jaime Modiano (Addgene plasmid # 86651; http://n2t.net/addgene:86651; RRID:Addgene:86651) (111). Human α3- nAChR-GFP was obtained from Sino Biological (HG29719-ACG). Human α3-nAChR R208I-GFP and E211N-GFP were generated from pcDNA3.1-CHRRA7-mGFP, and human α3-nAChR I284R-GFP and N287E-GFP were generated from human α3-nAChR-GFP by PCR-based QuickChange Site-Directed Mutagenesis Kit (Agilent) according to the manufacturer’s protocol. Human α3-nAChR I284R/N287E-GFP was generated by two sequential mutagenesis from human α3-nAChR-GFP. The following primers were used for mutagenesis; R208I (5’-GGA ATC CCC GGC AAG AGG AGT GAA ATA TTC TAT GAG TGC TGC-3’ and 5’-CCT TAG GGG CCG GCC TTC TCC TCA CTT TAT AAG ATA CTC ACG ACG-3’), E211N (5’-AGG TTC TAT AAC TGC TGC AAA GAG CCC TAC CCC GAT GTC-3’ and 5’-TCC AAG ATA TTG ACG AGC TTT CTC GGG ATG GGG GTA CAG-3’), I208R (5’-CCA GCC TAC AAA CAC GAC CGC AAG TAC AAC TGC TGC-3’ and 5’-GCA GCA GTT GTA CTT GCC GTG GTT TTT GTA GCC TGG-3’) and N211E (5’-GGC TAC AAA CAC GAC ATC AAC TAC GAG TGC TGC GAG GAG-3’ and 5’-CTC CTC CTC GCA GCA CTC GTA CTT GAT GTC GTG TTT GTA GCC CGC-3’); bold and italic nucleotides indicate mutations introduced.

Coimmunoprecipitation

Co-IP experiments were performed using a Co-IP kit (Pierce) following the manufacturer’s protocol with samples from three independently prepared cultures as carried out previously (50). Two micromolar soluble Aβ42 was added to total cell lysates (200 μl), and 20 μl of cell lysates with Aβ42 was collected as the input. A volume of 180 μl of cell lysates incubated with Aβ42 was pulled down with anti-GFP antibody. As a negative control, anti-actin was used. Immunoprecipitated samples were applied to immunoblots. To determine the effects of the Aβcore peptide, lysates were incubated with 2 μM Aβ42 and 5 μM active or inactive Aβcore peptide for 18 h and immunoprecipitated with an anti-GFP antibody.

Computational modeling

Computational peptide docking of the N terminus of Aβ into the α7-nAChR-AChBP (the acetylcholine-binding protein) chimera (55) was performed using the CABS-dock server for flexible protein–peptide docking (56). For the α7-nAChR-AChBP chimera, the X-ray crystallographic structure encompassing two adjacent α subunits containing the ligand-binding domain, equivalent in all five sites in the pentameric receptor, was used in a flexible protein–peptide docking.

GCaMP Ca2+ imaging

GCaMP Ca2+ imaging was carried out by the previously reported method (32, 47). DIV 4 neurons were transfected with pGP-CMV-GCaMP6f (a gift from Douglas Kim, Addgene plasmid # 40755; http://n2t.net/addgene:40755; RRID:Addgene_40755) (112) for imaging hippocampal pyramidal cells or pAAV-mDlx-GCaMP6f-Fishell-2 (a gift from Gordon Fishell, Addgene plasmid # 83899; http://n2t.net/addgene:83899; RRID:Addgene:83899) (113) for imaging interneurons by using Lipofectamine 2000 (Life Technologies) according to the manufacturer’s protocol. Neurons were imaged DIV 12 to 14. The transfection efficiency was around 2%, and no obvious cellular toxicity has been observed. Neurons were grown in Neurobasal Medium without phenol red (Life Technologies) and with B27 supplement (Life Technologies), 0.5 mM Glutamax (Life Technologies), and 1% penicillin/streptomycin (Life Technologies) for 8 to 10 days after transfection and during the imaging. Glass-bottom dishes were mounted on a temperature-controlled stage on an Olympus IX73 microscope and maintained at 37 °C and 5% CO2 using a Tokai-Hit heating stage and digital temperature and humidity controller. For GCaMP6f, the images were captured with a 10-ms exposure time and a total of 100 images were obtained with a 500-ms interval. Fmin was determined as the minimum fluorescence value during the imaging. Total Ca2+ activity was obtained by 100 values of ΔF/Fmin = (Fi – Fmin)/Fmin in each image, and values of ΔF/Fmin < 0.1 were rejected due to bleaching. Ten to 20 neurons were used for imaging in each individual experiment, and one individual neuron was assayed in an image.

Surface biotinylation

Surface biotinylation was performed according to the previous studies (32, 47, 101–103). Cells were washed with ice-cold PBS containing 1 mM CaCl2 and 0.5 mM MgCl2 and incubated with 1 mg/ml Sulfo-NHS-SS-biotin (Thermo Scientific) for 15 min on ice. Following biotin incubation, neurons were washed with 20 mM glycine to remove the excess of biotin, and cells were lysed in 300 μl radioimmunoprecipitation assay buffer for 1 h. Ten percent of the total protein was separated as an input sample, and protein lysates were incubated overnight with streptavidin-coated beads (Thermo Scientific) at 4 °C under constant rocking. The beads containing surface biotinylated proteins were separated by centrifugation. Biotinylated proteins were eluted from streptavidin beads with SDS loading buffer. Surface protein fractions and their corresponding total protein samples were analyzed by immunoblots.

Chemical LTP

cLTP was performed by a modification of the previously described method (62, 67). Cells were washed with Mg2+-free buffer (150 mM NaCl, 5 mM KCl, 1 mM CaCl2, 33 mM glucose, 10 mM Hepes [pH 7.4], 20 μM bicuculline, 1 mM strychnine), treated with 200 μM glycine in Mg2+-free buffer for 5 min at 37 °C, and returned to Mg2+ buffer (Mg2+-free buffer and 2 mM MgCl2) for 20 min at 37 °C. Cells were then lysed with 100 μl radioimmunoprecipitation assay buffer, and cell lysates were used for immunoblots.

Immunoblots

Protein samples for biotinylation and cLTP were loaded on 10% glycine-SDS-PAGE gel. Co-IP samples were loaded on
16% Tricine-SDS-PAGE gel as described (114). SDS-PAGE gels were transferred to nitrocellulose membranes. The membranes were blocked (5% powdered milk) for 1 h at room temperature, followed by overnight incubation with the primary antibodies at 4 °C. The primary antibodies consisted of anti-GluA1 (Millipore, 1:2000), anti-GluA2 (Abcam, 1:2000), anti-phosphorylated GluA1 S845 (Millipore, 1:1000), anti-GFP (Torrey Pines, 1:2000), anti-Aβ (6E10, Covance, 1:2000), and anti-actin (Abcam, 1:2000) antibodies. Membranes were subsequently incubated by secondary antibodies for 1 h at room temperature and developed with Enhanced Chemiluminescence (Thermo Fisher Scientific). Protein bands were quantified using ImageJ (https://imagej.nih.gov/ij/). Immuno-blots were at least duplicated for quantitative analysis.

Statistics

Statistical comparisons were analyzed with the GraphPad Prism 9 software. Unpaired two-tailed Student t tests were used in single comparisons. For multiple comparisons, one-way ANOVA followed by Fisher’s least significant difference (LSD) test was used to determine statistical significance. Results are represented as mean ± standard deviation (SD), and p < 0.05 was considered the minimum for statistical difference.

Data availability

All data are contained within the article.

Supporting information—This article contains supporting information.

Acknowledgments—We thank members of the Kim laboratory for their generous support. In particular, we thank Rosaline Danzman, Luis Gomez Wulschner, Thomas McMillan, and Caleb Wipf for initiating the project. We also thank Drs Michael Tamkun, Josef Vigh, Frederic Hoerndli, and Susan Tsunoda for helpful discussion and providing reagents. We specially thank Dr SeungBeom Hong at King Abdullah University of Science and Technology for his help in structural analysis.

Author contributions—S. K. and R. A. N., conceptualization; J. P. R., S. A. S., and S. K., investigation; M. F. S. and R. A. N., methodology; J. P. R., S. A. S., and S. K., writing - original draft; S. K. and R. A. N., Writing - review & editing; J. P. R., S. A. S., R. A. N., and S. K., fundig acquisition; S. K., supervision.

Funding and additional information—This work is supported by the University of Hawai‘i Foundation Preclinical Alzheimer’s Research Fund (R. A. N.), the pilot program from the Colorado Clinical and Translational Sciences Institute (S. K.), College Research Council Shared Research Program from Colorado State University (S. K.), the Boettcher Foundation’s Webb-Waring Biomedical Research Program (S. K.), the Barry Goldwater Scholarship and Excellence in Education Foundation (J. P. R.), Astronaut Scholarship Foundation (J. P. R.), and Student Experiential Learning Grant from Colorado State University (J. P. R. and S. A. S.).

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: Aβ, beta-amyloid; AChBP, acetylcholine-binding protein; AD, Alzheimer’s disease; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptor; cLTP, chemical long-term potentiation; cO-IP, coimmunoprecipitation; DIV, days in vitro; GABA, γ-aminobutyric acid; LTP, long-term potentiation; nAChR, nicotinic acetylcholine receptor.

References

1. Selkoe, D. J. (2011) Alzheimer’s disease. Cold Spring Harb. Perspect. Biol. 3, a004457
2. Jahn, H. (2013) Memory loss in Alzheimer’s disease. Dialogues Clin. Neurosci. 15, 445–454
3. Ferreira, S. T., and Klein, W. L. (2011) The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiol. Learn. Mem. 96, 529–543
4. Small, D. H., Mok, S. S., and Bornstein, J. C. (2001) Alzheimer’s disease and Abeta toxicity: From top to bottom. Nat. Rev. Neurosci 2, 595–598
5. Palop, J. J., and Mucke, L. (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: From synapses toward neural networks. Nat. Neurosci. 13, 812–818
6. Selkoe, D. J. (2002) Alzheimer’s disease is a synaptic failure. Science 298, 799–799
7. Selkoe, D. J., and Hardy, J. (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608
8. Davies, P., and Maloney, A. I. (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2, 1403
9. Schliebs, R., and Arendt, T. (2011) The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 221, 555–563
10. Nordberg, A. (2001) Nicotinic receptor abnormalities of Alzheimer’s disease: Therapeutic implications. Biol. Psychiatry 49, 200–210
11. Kadir, A., Almkvist, O., Wall, A., Langston, B., and Nordberg, A. (2006) PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease. Psychopharmacology 188, 509–520
12. Ferreira-Vieira, T. H., Guimaraes, I. M., Silva, F. R., and Ribeiro, F. M. (2016) Alzheimer’s disease: Targeting the cholinergic system. Curr. Neuropharmacol. 14, 101–115
13. Svensson, A. L., Alafuzoff, I., and Nordberg, A. (1992) Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Res. 596, 142–148
14. Mulugeta, E., Karlsson, E., Islam, A., Kalaria, R., Mangat, H., Winblad, B., and Adem, A. (2003) Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients. Brain Res. 960, 259–262
15. Ge, S., and Dani, J. A. (2005) Nicotinic acetylcholine receptors at glutamate synapses facilitate long-term depression or potentiation. J. Neurosci. 25, 6084–6091
16. Heinritz, K., Beck, M., Schliebs, R., and Perez-Polo, J. R. (2006) Toxicity mediated by soluble oligomers of beta-amyloid(1–42) on cholinergic SN565.B5.G4 cells. J. Neurochem. 98, 1930–1945
17. Jurgensen, S., and Ferreira, S. T. (2010) Nicotinic receptors, amyloid-beta, and synaptic failure in Alzheimer’s disease. J. Mol. Neurosci. 40, 221–229
18. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovskiy, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., and Klein, W. L. (1998) Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95, 6448–6453
19. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., Bush, A. I., and Masters, C. L. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann. Neurol. 46, 860–866
20. Auld, D. S., Kar, S., and Quirion, R. (1998) Beta-amyloid peptides as direct cholinergic neuromodulators: A missing link? Trends Neurosci. 21, 43–49
Coactivation of α7- and α4β2-nAChRs reverses Aβ effects

21. Liu, Q., Kawai, H., and Berg, D. K. (2001) Beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 98, 4734–4739

22. Pettit, D. L., Shao, Z., and Yakel, J. L. (2001) beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J. Neurosci. 21, RC120

23. Pym, L., Kemp, M., Raymond-Delpech, V., Buckingham, S., Boyd, C. A., and Sattelle, D. (2005) Subtype-specific actions of beta-amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4) expressed in Xenopus laevis oocytes. Br. J. Pharmacol. 146, 964–971

24. Albuquerque, E. X., Pereira, E. F., Alkondon, M., and Rogers, S. W. (2003) Nicotinic acetylcholine receptors of muscles and nerves: Comparison of their structures, functional roles, and vulnerability to pathology. Ann. N. Y. Acad. Sci. 998, 41–52

25. Lindstrom, J. M. (2003) Nicotinic acetylcholine receptors of muscles and nerves: Important new players in brain function. Eur. J. Pharmacol. 393, 3–10

27. Thompson, S., Lancot, K. L., and Herrmann, N. (2004) The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease. Expert Opin. Drug. Saf. 3, 425–440

28. Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., and Kivipelto, M. (2010) Alzheimer’s disease: Clinical trials and drug development. Lancet Neurol. 9, 702–716

29. Parri, H. R., Hernandez, C. M., and Dineley, K. T. (2011) Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer’s disease. Biochem. Pharmacol. 82, 931–942

32. Sun, J. L., Stokoe, S. A., Roberts, J. P., Sathler, M. F., Nip, K. A., Wu, J., Kuo, Y. P., George, A. A., Xu, L., Hu, J., and Lukas, R. J. (2004) Regulation of presynaptic Ca2+, synaptic plasticity and contextual fear conditioning by a N-terminal beta-amyloid fragment. J. Neurosci. 34, 14210–14218

34. Son, J. H., and Winzer-Serhan, U. H. (2008) Expression of neuronal nicotinic receptors in Alzheimer’s disease. Int. J. Alzheimers Dis. 2010, 548913

35. Lawrence, J. L., Tong, M., Alfulaiji, N., Sherrin, T., Contarino, M., White, M. M., Bellinger, F. P., Todorovic, C., and Nichols, R. A. (2014) Amyloid-beta peptide inhibits synapse formation and maturation via the alpha4beta2 nicotinic acetylcholine receptor. J. Neurosci. 34, 7160–7172

36. Olivero, G., Grilli, M., Chen, J., Preda, S., Mura, E., Govoni, S., and Preda, S. (2005) Amyloid beta(1-42) peptide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors. J. Biol. Chem. 280, 26942–26949

37. Thompson, S., Lanctot, K. L., and Herrmann, N. (2004) The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease. Expert Opin. Drug. Saf. 3, 425–440

38. Marchi, M. (2014) Effects of soluble beta-amyloid on the release of neurotransmitters from rat brain synaptosomes. J. Comp. Neurol. 522, 286–295

39. Barykin, E. P., Garifulina, A. I., Tolstova, A. P., Anashkina, A. A., Adzhe, A., Mezentsev, Y. V., Shelukhina, I. V., Kozin, S. A., Tsetlin, V. I., and Makarov, A. A. (2020) Tetrapeptide Ac-HAEE-NH2 protects alpha4beta2 nAChR from inhibition by Abeta. Int. J. Mol. Sci. 21, 6272

40. Gleichmann, M., and Mattson, M. P. (2011) Neuronal calcium homeostasis and dysregulation. Antioxid. Redox Signal 14, 1261–1273

41. Sztukowski, K., Kip, N., Ostwald, P. N., Sathler, M. F., Sun, J. L., Shou, J., Jorgensen, E. T., Brown, T. E., Elder, J. H., Miller, C., Hofmann, F., VandeWoude, S., and Kim, S. (2018) HIV induces synaptic hyperexcitability via cGMP-dependent protein kinase II activation in the FIV infection model. PLoS Biol. 16, e2005315

42. Lombardo, S., and Maskos, U. (2015) Role of the nicotinic acetylcholine receptor in Alzheimer’s disease pathology and treatment. Neuropharmacology 96, 255–262

43. Parri, R. H., and Dineley, T. K. (2010) Nicotinic acetylcholine receptor interaction with beta-amyloid: Molecular, cellular, and physiological consequences. Curr. Alzheimer Res. 7, 27–39

44. Wang, H. Y., Li, W., Benedetti, N. J., and Lee, D. H. (2003) Alpha7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. J. Biol. Chem. 278, 31547–31555

45. Li, S. X., Huang, S., Bres, N., Novidomi, K., Delissiani, C. D., Sine, S. M., and Chen, L. (2011) Ligand-binding domain of an alpha7-nicotinic receptor chimera and its complex with agonist. Nat. Neurosci. 14, 1253–1259

46. Tong, M., Arora, K., White, M. M., and Nichols, R. A. (2011) Role of key aromatic residues in the ligand-binding domain of alpha7 nicotinic receptors in the agonist action of beta-amyloid. J. Biol. Chem. 286, 34373–34381

47. Blaszczyszyn, M., Kurcinski, M., Kouza, M., Wieteska, L., Debinski, A., Kolinski, A., and Kmiecik, S. (2016) Modeling of protein-peptide interaction using the CABS-dock web server for binding site search and flexible docking. Methods 93, 72–83

48. Malinow, R., and Malenka, R. C. (2002) AMPA receptor trafficking and synaptic plasticity. Annu. Rev. Neurosci. 25, 103–126

49. Minano-Molina, A. J., Espaha, J., Martin, E., Barreda-Zahonero, B., Fado, R., Sole, M., Trullas, R., Saura, C. A., and Rodriguez-Alvarez, J. (2011) Soluble oligomers of amyloid-beta peptide disrupt membrane function in the temporal cortex of patients with Alzheimer’s disease. J. Neurochem. 74, 237–243
trafficking of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor contributing to early synaptic dysfunction. J. Biol. Chem. 286, 27311–27321

59. Zhao, W. Q., Santini, F., Breese, R., Ross, D., Zhang, X. D., Stone, D. J., Ferrer, M., Townsend, M., Wolfe, A. L., Seager, M. A., Kinney, G. G., Shughrue, P. J., and Ray, W. J. (2010) Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. J. Biol. Chem. 285, 7619–7632

60. Rui, Y., Gu, J., Yu, K., Hartzell, H. C., and Zheng, J. Q. (2010) Inhibition of AMPA receptor trafficking at hippocampal synapses by beta-amyloid oligomers: The mitochondrial contribution. Mol. Brain 3, 10

61. Guntupalli, S., Jang, S. E., Zhu, T., Huganir, R. L., Widagdo, J., and Anggono, V. (2017) GluA1 subunit ubiquitination mediates amyloid-beta-induced loss of surface alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. J. Biol. Chem. 292, 8186–8194

62. [preprint] Sathler, M. F., Khatri, L., Roberts, J. P., Kubrusly, R. C. C., Sathler, M. F., Khatri, L., Roberts, J. P., Kubrusly, R. C. C., Guntupalli, S., Jang, S. E., Zhu, T., Huganir, R. L., Widagdo, J., and Anggono, V. (2017) GluA1 subunit ubiquitination mediates amyloid-beta-induced loss of surface alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. J. Biol. Chem. 292, 8186–8194

63. Rui, Y., Gu, J., Yu, K., Hartzell, H. C., and Zheng, J. Q. (2010) Inhibition of AMPA receptor trafficking at hippocampal synapses by beta-amyloid oligomers: The mitochondrial contribution. Mol. Brain 3, 10

64. Li, S., Jin, M., Koeglsperger, T., Shepardson, N. E., Shankar, G. M., and Landis, B. W. (2009) AMPA receptor trafficking and cell-surface expression are regulated by NMDA receptors in cultured hippocampal neurons. J. Neurosci 29, 603–610

65. Le, C., Ji, J., Koeglsperger, T., Shepardson, N. E., Shankar, G. M., and Landis, B. W. (2009) AMPA receptor trafficking and cell-surface expression are regulated by NMDA receptors in cultured hippocampal neurons. J. Neurosci 29, 603–610
Coactivation of α7- and α4β2-nAChRs reverses Aβ effects

96. Bitner, R. S., Bunnelle, W. H., Anderson, D. J., Briggs, C. A., Buccafusco, J., Curzon, P., Decker, M. W., Frost, J. M., Gronlien, J. H., Gubbins, E., Li, J., Malyysz, J., Markosyan, S., Marsh, K., Meyer, M. D., et al. (2007) Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J. Neurosci. 27, 10578–10587

97. Cincotta, S. L., Yorek, M. S., Moschak, T. M., Lewis, S. R., and Rodefer, J. S. (2008) Selective nicotinic receptor agonist agonists: Potential therapies for neuropsychiatric disorders with cognitive dysfunction. Curr. Opin. Investig. Drugs 9, 47–56

98. Redrobe, J. P., Nielsen, E. O., Christensen, J. K., Peters, D., Timmermann, D. B., and Olsen, G. M. (2009) Alpha7 nicotinic acetylcholine receptor activation ameliorates scopolamine-induced behavioural changes in a modified continuous Y-maze task in mice. Eur. J. Pharmacol. 602, 58–65

99. Vicens, P., Ribes, D., Torrente, M., and Domingo, J. L. (2011) Behavioral effects of PNU-282987, an alpha7 nicotinic receptor agonist, in mice. Behav. Brain Res. 216, 341–348

100. Levin, E. D., and Christopher, N. C. (2002) Persistence of nicotinic agonist RJP2403-induced working memory improvement in rats. Drug Develop. Res. 55, 97–103

101. Kim, S., Titcombe, R. F., Zhang, H., Khatri, L., Girma, H. K., Hofmann, F., Arancio, O., and Ziff, E. B. (2015) Network compensation of cyclic GMP-dependent protein kinase II knockout in the hippocampus by Ca2+-permeable AMPA receptors. Proc. Natl. Acad. Sci. U. S. A. 112, 3122–3127

102. Kim, S., Violette, C. J., and Ziff, E. B. (2015) Reduction of increased calcineurin activity rescues impaired homeostatic synaptic plasticity in presenilin 1 M146V mutant. Neurobiol. Aging 36, 3239–3246

103. Kim, S., and Ziff, E. B. (2014) Calcineurin mediates synaptic scaling via synaptic trafficking of Ca2+-permeable AMPA receptors. PLoS Biol. 12, e1001900

104. Stine, W. B., Jr., Dahlgren, K. N., Krafft, G. A., and LaDu, M. J. (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278, 11612–11622

105. Krashia, P., Moroni, M., Broadbent, S., Hofmann, G., Kracun, S., Beato, M., Groot-Kormelink, P. J., and Sivilotti, L. G. (2010) Human α3β4 neuronal nicotinic receptors show different stoichiometry if they are expressed in Xenopus oocytes or mammalian HEK293 cells. PLoS One 5, e13611

106. Nelson, M. E., Kuryatov, A., Choi, C. H., Zhou, Y., and Lindstrom, J. (2003) Alternate stoichiometries of α4β2 nicotinic acetylcholine receptors. Mol. Pharmacol. 63, 332–341

107. Moroni, M., Zwart, R., Sher, E., Cassels, B. K., and Bermudez, I. (2006) α4β2 nicotinic receptors with high and low acetylcholine sensitivity: Pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol. Pharmacol. 70, 755–768

108. Broadbent, S., Groot-Kormelink, P. J., Krashia, P. A., Harkness, P. C., Millar, N. S., Beato, M., and Sivilotti, L. G. (2006) Incorporation of the β3 subunit has a dominant-negative effect on the function of recombinant central-type neuronal nicotinic receptors. Mol. Pharmacol. 70, 1350–1357

109. Wang, Y., Xiao, C., Indersmitten, T., Freedman, R., Leonard, S., and Lester, H. A. (2014) The duplicated α7 subunits assemble and form functional nicotinic receptors with the full-length α7. J. Biol. Chem. 289, 26451–26463

110. Nashmi, R., Dickinson, M. E., McKinney, S., Jareh, M., Labarca, C., Fraser, S. E., and Lester, H. A. (2003) Assembly of α4β2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: Effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons. J. Neurosci. 23, 11554–11567

111. Oloris, S. C., Frazer-Abel, A. A., Jubala, C. M., Fosmire, S. P., Helm, K. M., Robinson, S. R., Korpela, D. M., Duckett, M. M., Baksh, S., and Modiano, J. F. (2010) Nicotine-mediated signals modulate cell death and survival of T lymphocytes. Toxicol. Appl. Pharmacol. 242, 299–309

112. Chen, T. W., Wardill, T. J., Sun, Y., Pulver, S. R., Renninger, S. L., Baohan, A., Schreiter, E. R., Kerr, R. A., Orger, M. B., Jayaraman, V., Looger, L. L., Svoboda, K., and Kim, D. S. (2013) Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature 499, 295–300

113. Dimidschstein, J., Chen, Q., Tremblay, R., Rogers, S. L., Saldi, G. A., Guo, L., Xu, Q., Liu, R., Lu, C., Chu, J., Grimley, J. S., Krostag, A. R., Kaykas, A., Avery, M. C., Rashid, M. S., et al. (2016) A viral strategy for targeting and manipulating interneurons across vertebrate species. Nat. Neurosci. 19, 1743–1749

114. Haider, S. R., Reid, H. J., and Sharp, B. L. (2012) Tricine-SDS-PAGE. Methods Mol. Biol. 869, 81–91